[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=a857397406b6dc4c0ee574703bc3cd3b494631afecf241d5f93c5b6415faca51",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735836360,
      "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 132327316,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=a857397406b6dc4c0ee574703bc3cd3b494631afecf241d5f93c5b6415faca51"
    }
  },
  {
    "ts": null,
    "headline": "1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street",
    "summary": "Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) started 2024 on a strong note and performed well through the first half of the year.  Regeneron's stock could soar by 50% in the next year from its current levels if we go by its average price target of $1,053 (according to Yahoo!  Should investors rush to buy Regeneron's shares?",
    "url": "https://finnhub.io/api/news?id=6b6a301528785e0c6aef03ad723ec9e6ab4213ad75337ed4c4d2ad3d06f75d71",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735830000,
      "headline": "1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street",
      "id": 132246223,
      "image": "https://g.foolcdn.com/editorial/images/802113/elderly-person-sitting-on-a-bed.jpg",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) started 2024 on a strong note and performed well through the first half of the year.  Regeneron's stock could soar by 50% in the next year from its current levels if we go by its average price target of $1,053 (according to Yahoo!  Should investors rush to buy Regeneron's shares?",
      "url": "https://finnhub.io/api/news?id=6b6a301528785e0c6aef03ad723ec9e6ab4213ad75337ed4c4d2ad3d06f75d71"
    }
  },
  {
    "ts": null,
    "headline": "After Two Stellar Years for Stocks, It’s Time to Play Defense",
    "summary": "After Two Stellar Years for Stocks, It’s Time to Play Defense",
    "url": "https://finnhub.io/api/news?id=2ad92ea1ae64fd8ed931b94248c55f25ee9cda95c4ef952a856fa0a68bff6d58",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735783200,
      "headline": "After Two Stellar Years for Stocks, It’s Time to Play Defense",
      "id": 134152124,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "After Two Stellar Years for Stocks, It’s Time to Play Defense",
      "url": "https://finnhub.io/api/news?id=2ad92ea1ae64fd8ed931b94248c55f25ee9cda95c4ef952a856fa0a68bff6d58"
    }
  }
]